EGFR and pancreatic neoplasm: [17] Even erlotinib, whose effect is modest in pancreatic cancer, can improve first-line progression-free survival (PFS) in patients with EGFR-mutations (about 8–30% depending upon ethnicity) from 4.6 to 13 months.